Integer interim CEO gets ‘interim’ removed from title

Share

Integer CEO Joe Dziedzic

Integer CEO Joe Dziedzic [Image courtesy of Integer]

Medical device contract manufacturing giant Integer Holdings Co. said today that interim CEO Joseph Dziedzic will take over the company for good.

Dziedzic is a former Integer board member who took over in March after Thomas Hook stepped down from the top spot. He’s entered into a new three-year employment agreement with the Frisco, Texas–based company, effective today.

Dziedzic was EVP and CFO for The Brink’s Co. from 2009 to 2016. Before Brink’s, he was at General Electric for 20 years, holding leadership roles in six businesses, including GE Medical Systems.

“After conducting a comprehensive search for a permanent president and CEO, the choice was clear. Joe’s deep understanding of our business, stemming from his service on the [Integer] board since 2013, coupled with his prior executive experience and the skillful leadership he demonstrated during his service as our interim CEO, have shown him to be an ideal fit,” said Bill Sanford, Integer’s chairman of the board.

Formed in 2015 from the merger of Greatbatch and Lake Region Medical, Integer appears to be turning a corner. Much of the integration is now complete at the $1.4 billion-a-year company, which has 10,000 employees and 26 manufacturing facilities.

Revenue – down 4% on a comparable results basis in 2016 – was up 4% year-over-year during the first three months of 2017. Integer’s stock is up nearly 50% for the year, trading at more than $40 per share.

“This is an exciting time for Integer,” Dziedzic said. “As the market leader in MDO manufacturing, we have unrivaled capabilities to serve our customers’ needs across the full range of our product continuum, from medical device components to full-system solutions and devices.”

[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Speak Your Mind

*